3MO HER2 expression and early response to patritumab deruxtecan (HER3-DXd) in early-stage hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer (BC): A correlative analysis from SOLTI-TOT-HER3 trial
Fara Brasó‐Maristany(Hospital Clínic de Barcelona), Aleix Prat(Hospital Clínic de Barcelona), M.A. Arumi de Dios(Vall d'Hebron Hospital Universitari), Claudette Falato(Karolinska Institutet), Guillermo Villacampa(Vall d'Hebron Institut de Recerca), J.M. Ferrero-Cafiero(Solti), F.J. Salvador Bofill(Hospital Universitario de Valme), J. Cruz Jurado(Hospital Universitario de Canarias), Tomás Pascual(Breast Cancer Research Foundation), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Mafalda Oliveira(Vall d'Hebron Institut de Recerca), Mireia Margelí Vila(Institut Català d'Oncologia), Stephen Esker(Daiichi Sankyo (United States)), Olga Martínez‐Sáez(Breast Cancer Research Foundation), A. Santhanagopal(Daiichi Sankyo (United States)), P-D. Fan(Daiichi Sankyo (United States)), P. Tolosa Ortega(Hospital Universitario 12 De Octubre), Juan Miguel Cejalvo(Universitat de València)
Cited by 0
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
|Breast Cancer Research|2010|2.1k
Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
|New England Journal of Medicine|2019|1.3k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k